SYROS PHARMACEUTICALS INC's ticker is and the CUSIP is 87184Q206. A total of 52 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,245,511 | +35.4% | 1,581,142 | +8.0% | 0.25% | +56.5% |
| Q2 2023 | $4,611,707 | +90.9% | 1,464,034 | +61.8% | 0.16% | +101.2% |
| Q1 2023 | $2,415,362 | -25.2% | 904,630 | +0.5% | 0.08% | +14.3% |
| Q4 2022 | $3,231,000 | -44.3% | 900,000 | 0.0% | 0.07% | -40.7% |
| Q3 2022 | $5,796,000 | – | 900,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 868,403 | $3,117,567 | 3.03% |
| Bain Capital Life Sciences Investors, LLC | 2,124,694 | $7,628 | 0.85% |
| Samsara BioCapital, LLC | 881,450 | $3,164,406 | 0.68% |
| Altium Capital Management LP | 315,070 | $1,131,101 | 0.58% |
| Omega Fund Management, LLC | 251,270 | $902,059 | 0.30% |
| Artal Group S.A. | 1,463,829 | $5,255 | 0.29% |
| DAFNA Capital Management LLC | 265,878 | $954,502 | 0.27% |
| CVI Holdings, LLC | 425,500 | $1,527,545 | 0.20% |
| Flagship Pioneering Inc. | 993,848 | $3,567,914 | 0.11% |
| Avidity Partners Management LP | 900,000 | $3,231,000 | 0.07% |